News

hbs

Launching Our In Silico Service! Cureline Baltic uses a deep learning based technology that predicts molecule properties with unparalleled accuracy, rivaling experimental precision. It led to the discovery of new preclinical leads at negligible costs. Its versatility across therapeutic areas has been validated by independent laboratories in virology and oncology.

Engineered E. coli Nissle 1917 for delivery of bioactive IL‑2 for cancer immunotherapy

We’re proud to announce that Cureline Baltic is getting busy with networking this year! We have more than a few conferences lined up and are excited to enliven our attendance with insights into the scientific industry’s best global innovators. Other than looking forward to meeting some of the world’s best pioneers, we’re welcoming of discussions on potential collaborations in translational preclinical research!

At Cureline Group, we understand that effective R&D projects require more than just expertise—they demand a strategic approach for guaranteed success. Our R&D consulting is designed to enhance your R&D efforts by providing comprehensive support in study and research plan creation, scientific literature analysis, regulatory compliance, securing research funding, and more.

Our Director of Laboratory Animals Research, Vytautas Baranauskas, authored an article discussing Rabbit models of dry eye disease in the context of preclinical studies. At Cureline Baltic, we offer our expertise and support to assist you in the integration of these techniques into your research. Read the article to know what Rabbit models are best for dry eye disease.

At Cureline Baltic, we are committed to fostering a diverse and inclusive workplace where all employees, regardless of gender, have equal opportunities for personal and professional growth. We recognize that gender equality is not only a matter of social justice but also a vital component of a thriving and innovative organization. This Gender Equality Plan outlines our commitment and strategies to create an environment where everyone can flourish.

Our Preclinical Laboratory Animal Researcher, Jonas Mingaila, authored an article discussing Gut Microbiota Transplantation in the context of preclinical studies. At Cureline Baltic, we offer our expertise and support to assist you in the integration of these techniques into your research. Read the article to know what method is best for Gut Microbiota Transplantation.

Double Barcoding Technology is a new method, that allows monitoring drug effects on primary tumors and metastasis of co-injected cancer cell lines at the level of individual cells. By using two distinct DNA barcodes and uniquely tagging individual cells, double barcoding technology allows quantification of clone and metastasis sizes.

According to McKinsey & Company, a global management consulting firm, the biotechnology industry is growing. It shows that while large pharma companies are expected to grow R&D spending at a rate of 4 percent annually—to $234 billion for the industry in 2025—R&D spending in biotech is forecast to grow twice as fast, at up to 8 percent per year. CRO revenues also are expected to grow, reaching $46 billion by 2025, up more than 40 percent from 2020 (Graph1). This growth will be largely driven by growing product pipelines in biotech, coupled with a trend toward biotech companies retaining their assets longer.

We are delighted to announce Careline’s participation in the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11th to 15th, 2023 at the Hynes Convention Center in Boston, Massachusetts!

We are delighted to announce Cureline Baltic’s participation in the Life Science Baltics 2023 event, happening on September 20-21 in Vilnius, Lithuania!

Cureline Baltic, a global provider of preclinical and translational research services in the field of biotechnology and life sciences, is proud to announce its successful participation in a series of business missions and networking events across various international locations. These recent endeavors have further solidified Cureline Baltic's position as a global player in the contract research organization (CRO) industry.

It has been an exciting journey for the Cureline Group, from the time CEO Dr. Olga Potapova spearheaded the establishment of the company in 2003, up to where it is today. In preparing for the company's 20th anniversary in 2023, the key members of Cureline Group gathered in Turkey for a management conference in order to review and evaluate the business performance of the growing organization, introduce new initiatives and have quality time together.

Cureline Baltic COO Agne Vaitkeviciene has presented Cureline Group - Global Translational CRO activities in preclinical and translational research at Bioplus Interphaex Korea 2022.

Cureline, a US-based provider of human biospecimens (HBS) to the global biomedical research community, is establishing a clinical operations and research team in Lithuania. The team will be comprised of MS and PhD level research and medical professionals and is set to begin operations in early 2021. Cureline’s presence adds to the continually growing community of US companies in Lithuania’s Life Sciences ecosystem.